Ginkgo Bioworks Holdings, Inc. (DNA) Stock Forecast
Data as of Jul 31, 2026Healthcare · Current price $8.06 (-0.19%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Aug 23, 2024 | Mark Massaro | BTIG | $7.00 | -13.2% |
| Mar 3, 2022 | Steven Mah | Cowen & Co. | $12.00 | +48.9% |
Top Analysts Covering DNA
DNA vs Sector & Market
| Metric | DNA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 5.00 | 2.24 | 2.42 |
| Analyst Count | 1 | 8 | 19 |
| Target Upside | +5.6% | +16366.1% | +18.0% |
| P/E Ratio | -1.39 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $38M | $38M | $39M | 1 |
| 2026-12-31 | $37M | $37M | $38M | 1 |
| 2027-03-31 | $40M | $40M | $41M | 1 |
| 2027-06-30 | $41M | $42M | $42M | 1 |
| 2027-09-30 | $41M | $42M | $43M | 1 |
| 2027-12-31 | $42M | $42M | $43M | 1 |
| 2028-12-31 | $289M | $296M | $303M | 1 |
| 2029-12-31 | $360M | $369M | $377M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-1.24 | $-1.21 | $-1.18 | 1 |
| 2026-12-31 | $-1.28 | $-1.25 | $-1.22 | 1 |
| 2027-03-31 | $-1.44 | $-1.41 | $-1.38 | 1 |
| 2027-06-30 | $-1.22 | $-1.19 | $-1.17 | 1 |
| 2027-09-30 | $-1.12 | $-1.09 | $-1.07 | 1 |
| 2027-12-31 | $-1.02 | $-1.00 | $-0.98 | 1 |
| 2028-12-31 | $-3.27 | $-3.18 | $-3.08 | 1 |
| 2029-12-31 | $-2.30 | $-2.24 | $-2.17 | 1 |
Frequently Asked Questions
What is the analyst consensus for DNA?
The consensus among 1 analysts covering Ginkgo Bioworks Holdings, Inc. (DNA) is Strong Sell with an average price target of $7.84.
What is the highest price target for DNA?
The highest price target for DNA is $12.00, set by Steven Mah at Cowen & Co. on 2022-03-03.
What is the lowest price target for DNA?
The lowest price target for DNA is $7.00, set by Mark Massaro at BTIG on 2024-08-23.
How many analysts cover DNA?
1 analysts have issued ratings for Ginkgo Bioworks Holdings, Inc. in the past 12 months.
Is DNA a buy or sell right now?
Based on 1 analyst ratings, DNA has a consensus rating of Strong Sell (5.00/5) with a +5.6% upside to the consensus target of $7.84.
What are the earnings estimates for DNA?
Analysts estimate DNA will report EPS of $-1.21 for the period ending 2026-09-30, with revenue estimated at $38M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.